ABVC BioPharma Amends Material Agreement Filing

TL;DR

**ABVC BIOPHARMA just amended an 8-K about a material agreement, so keep an eye out for details on what changed.**

AI Summary

ABVC BIOPHARMA, INC. filed an 8-K/A on February 29, 2024, amending a previous 8-K filing from November 20, 2023. The amendment pertains to an "Entry into a Material Definitive Agreement" and "Financial Statements and Exhibits." The company, incorporated in Nevada with IRS Employer Identification No. 26-0014658, operates in the pharmaceutical preparations industry.

Why It Matters

This amendment provides updated information regarding a material definitive agreement, which could impact ABVC BIOPHARMA's financial position or future operations.

Risk Assessment

Risk Level: medium — The filing indicates an amendment to a material definitive agreement, which could signify changes to significant contracts or partnerships, potentially altering the company's risk profile.

Key Players & Entities

• ABVC BIOPHARMA, INC. (company) — Registrant
• Nevada (company) — State of incorporation
• 001-40700 (company) — Commission File Number
• 26-0014658 (company) — IRS Employer Identification No.
• February 29, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
• $1,200,000 — ertible note in the principal amount of $1,200,000 (the " Offering "), for a purchase pric
• $1,000,000 — " Offering "), for a purchase price of $1,000,000 (the " Note "), on November 17, 2023 (t
• $2 — n stock at an initial exercise price of $2 per share, subject to adjustment. We a
• $1.00 — rsion price shall have a floor price of $1.00 (the "Amendment"). Additionally, the Am

Filing Documents

• ea0200878-8ka1_abvcbio.htm (8-K/A) — 27KB
• ea0200878ex10-2_abvcbio.htm (EX-10.2) — 23KB
• 0001213900-24-018524.txt ( ) — 226KB
• abvc-20231120.xsd (EX-101.SCH) — 3KB
• abvc-20231120_lab.xml (EX-101.LAB) — 33KB
• abvc-20231120_pre.xml (EX-101.PRE) — 22KB
• ea0200878-8ka1_abvcbio_htm.xml (XML) — 4KB

01 Entry into a Material Definitive

Item 1.01 Entry into a Material Definitive Agreement. On November 20, 2023, ABVC BioPharma, Inc. (the " Company ") reported in the initial Current Report on Form 8-K that it entered into a securities purchase agreement (the " Securities Purchase Agreement ") with Lind Global Fund II, LP (" Lind "), pursuant to which the Company issued Lind a secured, convertible note in the principal amount of $1,200,000 (the " Offering "), for a purchase price of $1,000,000 (the " Note "), on November 17, 2023 (the "Initial 8K"). Pursuant to the Offering, Lind also received a 5-year, common stock purchase warrant (the " Warrant ") to purchase up to 1,000,000 shares of the Company's common stock at an initial exercise price of $2 per share, subject to adjustment. We are filing this amendment to disclose that due to Nasdaq requirements, the parties entered into an amendment to the Note, pursuant to which the conversion price shall have a floor price of $1.00 (the "Amendment"). Additionally, the Amendment requires the Company to make a cash payment to Lind if in connection with a conversion, the conversion price is deemed to be the floor price. The foregoing description of the Amendment is qualified by reference to the full text of the Amendment, which is filed as an Exhibit hereto and incorporated herein by reference. Neither this Current Report on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company's securities in any state in which such offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and app

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit 10.1 Form of Note (incorporated by reference to Exhibit 10.2 of the 8K filed on November 20, 2023) 10.2 Form of Amendment 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. February 29, 2024 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 2

View Full Filing

View this 8-K/A filing on SEC EDGAR